Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
- A4056 AT13387Target: HSP90Summary: Hsp90 inhibitor
- A4061 IPI-504 (Retaspimycin hydrochloride)3 CitationTarget: HSP90Summary: Hsp90 inhibitor,novel, potent,selective
- A4064 NVP-BEP800Target: HSP90Summary: Oral Hsp90β inhibitor, novel, fully synthetic
- A8202 Abiraterone acetateTarget: Cytochrome P450 (CYP450)Summary: Cytochrome p450 17a1 inhibitor
- A4300 GW96621 CitationSummary: PPARγ antagonist
- A4316 KetoconazoleTarget: Cytochrome P450 (CYP450)Summary: Inhibitor of cyclosporine oxidase and testosterone 6 beta-hydroxylase
- A4347 Methotrexate2 CitationTarget: Folate AnalogueSummary: Folate antagonist,inhibits DFHR
- A4358 U-104Target: Carbonic AnhydrasesSummary: CAIX inhibitor
- B4900 Indoximod (NLG-8189)Summary: Indoleamine 2,3-dioxygenase (IDO) pathway inhibitor
- A8721 CBR-58841 CitationTarget: 3-phosphoglycerate dehydrogenaseSummary: selective inhibitor of PHGDH